Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference
25 September 2019 - 10:02PM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, today announced that it
will participate in the 2019 Cantor Global Healthcare Conference in
New York, NY. Patrick J. McEnany, Catalyst’s Chief Executive
Officer and Steven Miller, Ph.D., Chief Scientific Officer/Chief
Operating Officer will represent the company in a fireside chat and
will host one-on-one meetings on Wednesday, October 2nd, 2019.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis
(MuSK-MG), congenital myasthenic syndromes (CMS), and spinal
muscular atrophy (SMA) Type 3. Catalyst's new drug application for
Firdapse® (amifampridine) 10 mg tablets for the treatment of adults
with LEMS was approved in November 2018 by the U.S. Food &
Drug Administration ("FDA"), and Firdapse is now commercially
available in the United States. Prior to its approval,
Firdapse for LEMS had received breakthrough therapy designation and
orphan drug designation from the FDA.
Firdapse is currently being evaluated in
clinical trials for the treatment of MuSK-MG, CMS, and SMA Type 3
and has received Orphan Drug Designation from the FDA for
myasthenia gravis and CMS. Firdapse (amifampridine) 10 mg tablets
is the first and only approved drug in Europe for the
symptomatic treatment in adults with LEMS.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2018 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From May 2023 to May 2024